Screener
Castle Biosciences CSTL Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest income | 2,545 | 3,099 |
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
| Loss before income taxes | (14,413) | (26,271) |
| Income tax expense (benefit) | 109 | (423) |
| Net loss | $(14,522) | $(25,848) |
| Loss per share, basic and diluted | $(0.49) | $(0.90) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's other income (expense)?
- Castle Biosciences (CSTL) reported other income (expense) of -$439K in Q1 2026.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Castle Biosciences's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude